Progyny (NASDAQ:PGNY) Updates Q1 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its first quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.420-0.450 for the period, compared to the consensus EPS estimate of 0.390. The company issued revenue guidance of $319.0 million-$332.0 million, compared to the consensus revenue estimate of $344.9 million. Progyny also updated its FY 2026 guidance to 1.830-1.950 EPS.

Progyny Stock Up 4.3%

Shares of NASDAQ PGNY traded up $0.92 during mid-day trading on Thursday, hitting $22.25. 1,852,843 shares of the company were exchanged, compared to its average volume of 1,438,952. The stock has a 50 day simple moving average of $24.16 and a 200-day simple moving average of $23.14. Progyny has a 1-year low of $17.98 and a 1-year high of $28.75. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 35.32, a price-to-earnings-growth ratio of 1.31 and a beta of 0.96.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.24). Progyny had a net margin of 4.46% and a return on equity of 10.71%. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PGNY has been the subject of several analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Citigroup upgraded Progyny to an “outperform” rating in a research report on Tuesday, January 20th. JPMorgan Chase & Co. set a $35.00 target price on Progyny in a research note on Wednesday, January 21st. Canaccord Genuity Group lifted their price target on Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research note on Monday, November 17th. Finally, KeyCorp upped their price objective on Progyny from $30.00 to $32.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.80.

Institutional Investors Weigh In On Progyny

A number of institutional investors and hedge funds have recently modified their holdings of PGNY. Wellington Management Group LLP increased its stake in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares in the last quarter. Loomis Sayles & Co. L P purchased a new stake in Progyny during the fourth quarter worth $19,917,000. Ameriprise Financial Inc. grew its holdings in Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the last quarter. Norges Bank purchased a new position in shares of Progyny in the fourth quarter valued at $10,167,000. Finally, Qube Research & Technologies Ltd increased its position in shares of Progyny by 161.6% in the third quarter. Qube Research & Technologies Ltd now owns 457,015 shares of the company’s stock valued at $9,835,000 after buying an additional 282,322 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.